As of Nov 19, 2026, 2 of 2 active firms rate NAGE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NAGE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.02
Range $-0.02 – $-0.02 · 1 analysts · -189% YoY
Next period, 1 analysts expect Niagen Bioscience, Inc. to earn $-0.02 a share (range $-0.02 – $-0.02), versus $0.02 a year earlier. Full-year consensus is $0.02, growing to $-0.08 the year after.
REVENUE · NEXT QUARTER
$31.5M
Range $29.2M – $33.5M · 1 analysts · +0% YoY
Revenue is expected to reach $31.5M (range $29.2M – $33.5M), +0.0% year-over-year. Full-year consensus is $118.4M, rising to $137.1M next year.
Top analysts covering Niagen Bioscience, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NAGE.
#1
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$11.00+468.5% to target
Overall win rate
36%
+ Follow
#2
Sean McGowan
Roth MKM · Rank #510
Buy
$12.00+520.2% to target
Overall win rate
26%
+ Follow
#3
Susan Anderson
Canaccord Genuity · Rank #520
Buy
$10.00+416.8% to target
Overall win rate
31%
+ Follow
#4
JC
Jeffrey Cohen
Ladenburg Thalmann
Buy
$11.00+468.5% to target
Coverage
—
+ Follow
#5
IZ
Ilya Zubkov
Freedom Capital Markets
Buy
$9.00+365.1% to target
Coverage
—
+ Follow
NAGE stock forecast FAQ
What is NAGE's average 12-month price target?+
The 2 active firms with a live target average $10.50 for Niagen Bioscience, Inc. over the next 12 months, ranging from a $11.00 high to a $10.00 low, as of Nov 19, 2026.
Is NAGE stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NAGE?+
The Street-high target is $11.00 (HC Wainwright & Co.), and the Street-low is $10.00 (Canaccord Genuity). The average of all 2 active-firm targets is $10.50.
How many active Wall Street firms cover NAGE?+
2 active firms have a recognized rating on Niagen Bioscience, Inc. as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NAGE?+
Among analysts who currently cover NAGE, Raghuram Selvaraju of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #423). Their current call is Buy with a $11.00 target.
What is Niagen Bioscience, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.02 per share (range $-0.02 – $-0.02) across 1 analysts. Full-year EPS is projected at $0.02, rising to $-0.08 the following year.
How much revenue is Niagen Bioscience, Inc. expected to report next quarter?+
Consensus revenue is $31.5M (range $29.2M – $33.5M). Full-year revenue is projected at $118.4M, growing to $137.1M next year.
Have analysts been upgrading or downgrading NAGE lately?+
As of Nov 19, 2026, 2 of 2 active firms rate NAGE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NAGE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.